Gilead Sciences (GILD) Q4 and Annual 2025 Earnings
Gilead Sciences reported Q4 2025 revenue of $7.9B (+4.7% YoY), beat analyst consensus of $7.7B by $234.6M. Diluted EPS came in at $1.86 (-2.1% YoY), beat the $1.81 consensus by $0.05. Gilead Sciences reports across 3 business segments, led by Virology, Oncology, and Other Therapeutic Areas.
Financial Snapshot
Trailing eight quarters through Q4 2025
Q4 2025 Earnings FAQ
Common questions about Gilead Sciences's Q4 2025 earnings report.
Gilead Sciences (GILD) reported Q4 2025 earnings on February 10, 2026 after market close.
Gilead Sciences reported revenue of $7.9B and diluted EPS of $1.86 for Q4 2025.
Revenue beat the consensus estimate of $7.7B by $234.6M. EPS beat the consensus estimate of $1.81 by $0.05.
Compared to the same quarter a year prior, revenue grew 4.7% from $7.6B a year earlier and diluted EPS declined 2.1% from $1.90.
Gilead Sciences reports across 3 business segments, led by Virology, Oncology, and Other Therapeutic Areas. Segment-level financials are available on the company's metrics pages.
You can read the 8-K earnings release (0000882095-26-000003) and the 10-K periodic report (0000882095-26-000006) directly on SEC EDGAR. The filing index links above go to sec.gov.